Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Profusa ( (PFSA) ) is now available.
On November 19, 2025, Profusa, Inc. announced its financial and business highlights for the third quarter ending September 30, 2025. The company achieved significant milestones, including a merger with NorthView Acquisition Corporation, reducing net debt from $34 million to $14 million, and raising $9 million through equity and convertible debt. Profusa expanded its manufacturing capabilities and sales footprint, especially for its Lumee Oxygen platform in Europe, and aims for substantial revenue growth by 2030. The company plans to further reduce debt and capitalize on near-term opportunities in the European and US markets.
More about Profusa
Profusa, based in Berkeley, California, is a commercial stage digital health company specializing in the development of tissue-integrated sensors for continuous biochemical monitoring. The company aims to provide actionable, medical-grade data through its biosensors and intelligent data platform, targeting both personal and medical use.
Average Trading Volume: 12,238,146
Technical Sentiment Signal: Sell
Current Market Cap: $7.06M
See more data about PFSA stock on TipRanks’ Stock Analysis page.